COVID-19 and CLL

COVID-19: Implications for Patients With CLL

Keep abreast of ongoing developments in providing optimal care for patients with CLL during COVID-19 and evolving research into countering COVID-19–associated inflammatory cytokine production! Get expert perspectives on emerging data with focused commentaries, an FAQ module, and a “living” slideset regularly updated to incorporate the most important clinical findings on CLL and COVID-19.

Jeff P. Sharman, MD

Jacob D. Soumerai, MD

ClinicalThought

Hot Off the Press: New Data on the Use of Acalabrutinib to Manage Patients With Severe COVID-19

View ClinicalThought

What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?

Jeff P. Sharman, MD Released: June 16, 2020

ClinicalThought

Six Months Later: How COVID-19 Has Changed My Management of CLL

View ClinicalThought

With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.

Jacob D. Soumerai, MD Released: September 30, 2020

COVID-19: Implications for Patients With CLL

ClinicalThought

Hot Off the Press: New Data on the Use of Acalabrutinib to Manage Patients With Severe COVID-19

Six Months Later: How COVID-19 Has Changed My Management of CLL

Leaving the CCO site